Codexis Inc (CDXS)

$3.48 0.02 (0.58%)

13:16 EDT CDXS Stock Quote Delayed 30 Minutes

CDXS Stock Earnings: Codexis Beats EPS, Beats Revenue for Q1 2024

By InvestorPlace Earnings May 2, 2024

CDXS stock results show that Codexis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

3 Synthetic Biology Stocks Likely to Mint New Millionaires

The Next Nvidia: 3 AI Stocks That Could Break New Records

Time to Evolve: 3 Synthetic Biology Stocks to Sell Off Now

More Articles

Volume:

Previous Close -

Market Cap 224.95M

PE Ratio -3.74

EPS -0.93

Volume (Avg. Vol.) 133,888

Day's Range $3.42 - $3.51

52-Week Range $1.45 - $4.91

Dividend & Yield N/A (N/A)

CDXS Stock Predictions, Articles, and Codexis Inc News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Jul 15, 2022

Good morning! We're starting the last day of trading this week with a breakdown of the biggest pre-market stock movers for Friday!

7 Small-Cap Stocks to Consider for the Second Half of 2018

By James Brumley, InvestorPlace Feature Writer Jul 9, 2018

Small-cap stocks have been on a tear of late. Take the hint, and start your search with these seven top prospects.

Codexis stock climbs 11% on Roche licensing deal for DNA ligases (NASDAQ:CDXS)

From Seeking Alpha Feb 26, 2024

Codexis (CDXS) stock climbed 11% in post-market trading after the company said it had granted an exclusive global license to Roche (RHHBY) for its EvoT4 DNA and new dsDNA ligases.

Codexis gets $40M financing deal with Innovatus Capital Partners (NASDAQ:CDXS)

From Seeking Alpha Feb 13, 2024

Codexis secures $40 million loan facility from Innovatus Capital Partners, with $30 million upfront and potential for an additional $10 million.

Biggest stock movers today: Adobe, Ocular Therapeutix and more (NASDAQ:CDXS)

From Seeking Alpha Dec 14, 2023

Stock futures slightly rose in the premarket hours on Thursday following the Federal Reserve's indication of potential 75 basis points of rate cuts in 2024. Her

KeyBanc sees opportunity in tech-enabled drug discovery stocks (NASDAQ:ABCL)

From Seeking Alpha Dec 10, 2023

KeyBanc has initiated coverage of the tech-enabled drug discovery subsector, citing increasing demand for products that can help lower drug development costs. Read more here.

Analysts Offer Insights on Materials Companies: Codexis (CDXS), Tenaris SA (TS) and AdvanSix (ASIX)

From TipRanks Nov 12, 2022

There’s a lot to be optimistic about in the Materials sector as 3 analysts just weighed in on Codexis (

H.C. Wainwright Keeps Their Buy Rating on Codexis (CDXS)

From TipRanks Nov 7, 2022

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Codexis (CDXS – Research Report) today and set a price target of $15.00. The company...

ADVERTISEMENT